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Drug protein binding in chronic renal failure: Evaluation of nine drugs.
In this study, changes of protein binding of nine drugs were evaluated.
In addition, theophylline and phenytoin, the two drugs with the most
substantial and progressive decrease in protein binding, were further
studied by high performance liquid chromatography (HPLC)-fractions
of ultrafiltrate of normal and uremic serum, in an attempt to identify
substances causing drug protein binding inhibition. There was a marked
decline of the protein binding of theophylline, phenytoin and metho-
trexate (dialyzed patients vs. normals: —20.1, —16.0 and —15.1%,
respectively). There was a rise in the protein binding of propranolol,
cimetidine and clonidine. The changes observed for diazepam, prazosin
and imipramine were less marked. For phenytoin, theophylline, meth-
otrexate and diazepam, protein binding was inversely correlated to the
serum creatinine (r = 0.87, 0.80, 0.79 and 0.67, P < 0.001), and a less
pronounced but still significant positive correlation was found for
clonidine (r = 0.46, P < 0.01). Ultrafiltrate, obtained during a hemofil-
tration session, inhibited protein binding of theophylline and phenytoin
in a dose dependent way. After separation of this ultrafiltrate by HPLC,
it appeared that for both theophylline and phenytoin at least a part of
this inhibitory activity corresponded to the elution zone of hippuric
acid. For theophylline two other inhibitory zones were further recog-
nized: one corresponding to the elution zone of NaCl and one in which
the responsible substance remained unidentified. Hippuric acid in
solution inhibited protein binding of theophylline and phenytoin in a
dose dependent way. In conclusion, protein binding of several drugs
currently used in renal failure is affected in parallel with renal function,
which might affect the therapeutic effectiveness of the drugs. Further-
more, hippuric acid appears to play an important role in the defect of
the protein binding of theophylline and phenytoin.
The binding of drugs to plasma proteins in uremia remains a
source of major concern. The knowledge of binding percentages
and possible displacement effects is clinically important in the
adjustment of the administered dose to avoid intoxication
and/or undertreatment, in particular since the pharmological
action of drugs is dependent on their free, unbound fraction. In
contrast, the clinical monitoring of blood concentrations of
most drugs is based on determinations of total (bound plus
unbound) concentrations; thus changes in the fraction of bound!
unbound drug should be taken into account to avoid possible
side effects and to maximize drug effectiveness.
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Renal failure is thought to be associated with a change in
protein binding of drugs. The available literature applies to
several drugs [1—9], but a number of substances that are
frequently used in renal failure have not been evaluated.
Furthermore, studies investigating the factors that may be
responsible for changes in drug protein binding have been
scarce, and some of them based on indirect approaches, such as
the analysis of normal urine [10], or the use of non-biological
solutions [11].
Therefore, the present study was undertaken to evaluate
dynamic changes of protein binding of nine drugs that are
commonly used in renal failure patients. In addition, a further
study was undertaken in which theophylline and phenytoin, the
two drugs with the most substantial and progressive decrease in
protein binding, were submitted to further evaluation by high
performance liquid chromatography (HPLC)-fractions of ultra-
filtrate of normal and uremic serum, in an attempt to identify
substance(s) responsible for the drug protein binding inhibition.
Methods
Protein binding of normal and uremic serum
Sample collection and analysis. Serum was obtained from II
healthy volunteers, 18 non-dialyzed patients with renal failure
and 11 dialyzed patients, prior to the start of dialysis. Of the
dialyzed group, five patients were treated by conventional
hemodialysis with Cuprophan membranes (Bravo 500 or 512,
surface area 1.06 m2, BelIco, Mirandola, Italy), whereas the
remaining six patients were receiving hemodiafiltration therapy
with AN 69S membranes (Biospal S 3000, surface area 1.20 m2,
Hospal, Lyon, France), and a substitution volume of 10 liters.
Heparinization was performed with a heparin brand containing
no benzyl alcohol as preservative. Patients involved in the
study were selected for no intake of salicylates or related drugs.
Blood samples in the dialyzed patients were collected at the
start of dialysis. The results of the Cuprophan and AN69S
groups were pooled, since there were no major differences. In
addition to drug binding, the serum creatinine, total protein and
albumin concentration were also determined in the same sam-
ples by the Jaffé-reaction, the biuret and the brome chresol acid
methods, respectively.
Protein binding studies. Studies were performed with radio-
labeled theophylline, clonidine, imipramine, diazepam, cimeti-
dine, propranolol, prazosin and methotrexate (Amersham In-
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ternational, U.K.) and diphenylhydantoin (New England Nu-
clear, Boston, Massachusetts, USA).
The choice of the drugs was inspired by: I) their current use
in renal failure and 2) their easy availability as radiolabeled
substance.
Protein binding was evaluated in vitro by mixing 500 .d of
serum with 200 d of one of the drug solutions, followed by
incubation at 37°C for 30 minutes. Two aliquots of this mixture
(100 d each) were transferred into a small plastic vial contain-
ing 5 ml of scintillation cocktail (Opti-fluor. Packard, Brussels,
Belgium), for analysis of total drug concentration in a liquid
scintillation counter (Packard Tri-carb B 2450). Free drug was
separated from the bound fraction by centrifugation (1800 X g
for 15 mm) and ultrafiltration through an anisotropic hydrophyl-
lic ultrafiltration membrane (Centrifree microportion system,
Amicon, Danvers, Massachusetts, USA). Aliquots (100 l) of
the filtrate were processed for scintillation counting as de-
scribed above, for the estimation of free drug concentration.
DPM (disintegrations per minute) were calculated from the
measured CPM values in the radioactive solutions by a ESR
(external standard ratio) method. The mean of duplicate deter-
minations was established. Protein binding was calculated as a
percentage (bound fraction versus total).
None of the drugs under study was bound to the centrifree
ultrafiltration membrane by more than 10%, except for imipra-
mine (quantity retained on the membrane = 24.3%). Retention
for phenytoin and theophylline was 4.1 and 0.1%, respectively.
Influence of ultrafiltrate on protein binding
Ultrafiltrate was collected during hemofiltration of uremic
patients with the AN 69S membrane. The influence of ultrafil-
trate on protein binding of theophylline and phenytoin was
studied by lyophilizing 0.5, 1 and 2 ml of ultrafiltrate, and
adding it to 500 d of pooled normal serum. Protein binding was
evaluated and the percentage difference versus pooled normal
serum was determined. The sodium content of each of the
samples studied was measured by standard methods before
lyophilization.
Influence of NaG! on protein binding
Five hundred d of NaCI containing solutions (50, 100, 200,
300, 400, 500 and 600 mEq/liter) were lyophilized and the dry
substance was then added to 500 d of normal serum; protein
binding of theophylline and phenytoin was assessed.
When theophylline and phenytoin were diluted in a solution
containing 600 mEq/liter of sodium, no major change in the
binding of the two drugs to the centrifree ultrafiltration mem-
brane was observed, compared to a dilution in isotonic saline.
Influence of HPLC eluate on protein binding
Normal sera (N = 3), and ultrafiltrates (N = 4) obtained
during hemofiltration were further evaluated. These were sub-
mitted to a preliminary ultrafiltration over a Centrifree filter, as
a preparative procedure before HPLC. Two ml samples were
submitted to each HPLC-run. HPLC determinations were
undertaken with two LKB 2150 high pressure pumps and an
LKB 2152 gradient controller (LKB, Bromma, Sweden). The
analyses were performed on a RSiI reverse-phase C18 prepar-
ative column with a particle size of 10 p a length of 25 cm and
an inner diameter of 10 mm (Alltech Europe, Eke, Belgium). A
guard column (5 cm >< 4.6 mm) packed with Pellicular C18 (10
m) was used to protect the main column from contaminants.
Detailed operating conditions during this procedure have been
described elsewhere 1121. The Valco injector (Valco Instru-
ments Co., Houston, Texas, USA) was provided with a loop of
2 ml. The solvent gradient was linear from 100% ammonium
formate (0.05 jtmol/liter, pH 4.0) to 54% highly purified meth-
anol (Alltech Associate Inc., Deerfield, Illinois, USA) within 45
minutes. Flow rate was 3 mI/mm. The solvent and the column
were kept at room temperature. Ultraviolet detection was
performed by a UV photometer (LKB 2238 Uvicord Sli,
Bromma, Sweden) at 254 nm. Peaks were registered by an LKB
2210 two pen recorder (LKB, Bromma, Sweden). Three ml
eluate fractions collected during the first 30 minutes of the
HPLC-procedure, were sampled, lyophilized and rediluted ei-
ther in 500 jd water for the determination of the concentration
of Na, K4 and Cl, and osmolality, or in 500 d of normal
serum for the determination of protein binding of theophylline
and phenytoin as described above.
Identification of substances responsible fr protein binding
inhibition
To further identify substances potentially responsible for the
binding inhibition, the HPLC pattern of several known uremic
solutes was studied separately before and after addition to
uremic ultrafiltrate. These included: creatinine (20 mg/100 ml),
pseudo-uridine (0.90 mg/l00 ml), uric acid (0.95 mg/100 ml),
indoxyl sulphate (1.60 mg/100 ml) and hippuric acid (3.0 mg/100
ml). HPLC was performed after 3 ml of this solution was added
to I ml of H20, and was processed as described above. The
same solution was also added to I ml of uremic ultrafiltrate, and
analyzed. To assess the influence of ultrafiltrate, I ml of
ultrafiltrate and 3 ml of H,O were mixed, and processed and
analyzed in the same way.
Finally, five known uremic solutes were diluted in water to
different concentrations, equal to or above those currently
observed in renal failure: urea (200, 300, 400 and 500 mg/lOO
ml), creatinine (5, 10, 15, and 20 mg/l00 ml), indoxyl sulphate
(10, 20, 50, 100 and 200 mg/100 ml), hippuric acid (10, 20, 50,
100 and 200 mg/lOO ml) and pseudo-uridine (0.25, 0.50, 1, 2, and
5 mg/lOO ml). Five hundred d of these solutions were lyophi-
lized, added to 500 l of normal serum and protein binding of
both phenytoin and theophylline was determined.
Statistical evaluations
Values are given as means SD. Statistical comparison
between different groups was performed by Wilcoxon's test for
unpaired values. Regression-correlation analysis was obtained
by Spearman's test. Statistical significance was accepted for P
<0.05.
Results
Protein binding of normal and uremic serum
The percentage protein binding of the nine drugs under study
for different degrees of renal failure is shown in Table 1. There
was a marked and gradual decline of the protein binding of
theophylline, phenytoin and methotrexate which for hemodi-
alyzed patients reached values that were decreased by 20.1%,
16.0% and 15.1%, respectively, when compared to normals (P
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Table 1. Percent protein binding according to renal function
Sr Sí SCr
1.3 to 3.0 ,ngIIOO in! 3.0 to 6.0 rng/100 in! >6.0 mgIIOO mlN=6 N6 N=7
Theophylline 63.6 1.9 62.5 4.9 52.3 4.6' 48.4 8.7c
Phenytoin 91.6 0.7 87.9 l.4c 82.4 1.8c 81.7 2.7c
Methotrexate 42.8 1.6 44.5 5.7 40.4 6.0 36.2 9.!
Diazepam 98.3 1.0 98.1 0.3 97.8 0.4a 97.1
Prazosin 94.0 0.5 92.5 0.6c 91.1 0.3 89.9 0.6c
Imipramine 96.2 0.8 97.4 0.7' 97.4 0.2c 96.7 0.6
Propranolol 90.2 2.0 95.! l,IC 93.2 1.5i 94.1 1.8
Cimetidine 8.9 2.2 14.7 4.8c 17.1 2.7' J5.5 3,7C
Clonidine 44.4 7.1 54.1 5,4 50.0 3,4U 52.4 6.7
Values are expressed as means SD; Sr is serum creatinine.
a p < 0.05
b P < 0.02
P < 0.01, vs. S. < 1.3 mg/l00 ml (Wilcoxon's test for unpaired values).
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was less marked, although statistically significant (98.3 com-
pared with 96.6%). This alteration corresponded to a 100% rise
in the free fraction (from 1.7 to 3.4%). The protein binding of
prazosin and imipramine in dialyzed patients was not signifi-
cantly different from the control group, although minor but
significant differences were observed in non-dialyzed patients
with renal failure. Prazosin was characterized by a slight
decline of protein binding, whereas imipramine showed a minor
increase, There was a rise in the degree of protein binding of
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gressed.
For diazepam, methotrexate, theophylline and phenytoin,
there was a highly significant negative correlation between
serum creatinine levels and protein binding (Fig. 1, r = 0.67,
0.79, 0.80 and 0.87, respectively, P < 0.001). For clonidine, a
positive correlation was found that was also significant, albeit to
a lesser extent (r = 0.46, P < 0.01). The correlation was not
significant for cimetidine, imipramine, prazosin and propranolol
(r = 0.22, 0.26, 0.26 and 0.28, respectively, P > 0.05). The
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Fig. 1. Correlation—regression analysis (N = 40) between 'reatine,nia and the protein binding qf four drugs: diazepamn (A), mnethotrexate (B),
theophy!!ine (C), and phenytoin (D). The characteristics of the different regression lines were as follows:
- Diazepam: creatininemia = 30.7 — (3.03 x protein binding); r = 0.67, P < 0.001
- Methotrexate: creatininemia = 22.3 — (0.43 x protein binding); r 0.79, P < 0.001
- Theophylline: creatininemia = 26.0 — (0.37 x protein binding); r = 0.80, P < 0.001
- Phenytoin: creatininemia 56.6 — (0,60 x protein binding); r = 0.87. P < 0.001.
< 0.01 for all). The decrease in protein binding for diazepam propranolol, cimetidine and clonidine, when renal failure pro-
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Fig. 2. Percentage inhibition of protein binding (PB) versus normal
when lyophilisate of 0.5, / and 2 ml of ultrafihtrate is added to normal
serum, for theophylline (A) and phenytoin (B).
respective mean values of serum protein for the different groups
were 7.4 0.6 (Sr < 1.3 mg/100 ml), 7.3 0.6 (Scr: 1.3 to 3.0
mg/l00 ml), 7.3 0.5 (Scr: 3.0 to 6.0 mg/100 ml), 7.4 0.5 (Scr
> 6.0 mg/100 ml) and 6.6 0.7 gIlOO ml (hemodialyzed
patients). Only the latter value was significantly different from
the result obtained in healthy controls (Sc, < 1.3 mg/100 ml, P
<0.05). The respective serum albumin concentrations were 4.4
0.3, 4.3 0.5, 4.3 0.5, 4.5 0.3 and 4.1 0.8 mg/l00 ml.
None of these values were significantly different. No correla-
tion could be found between serum protein and albumin con-
centration on one hand and the protein binding of any of the
drugs on the other.
Influence of ultrafihtrate on protein binding
The influence of ultrafiltrate of uremic serum obtained during
hemofiltration on the protein binding of phenytoin and theo-
phylline was evaluated. Lyophilized ultrafiltrate (N = 5) was
added to normal serum and the degree of protein binding
inhibition was evaluated (Fig. 2). There was a gradual dose-
dependent decrease of the protein binding for both theophylline
and phenytoin with increasing quantities of added lyophilisate
(0.5, 1 and 2 ml). After the addition of 2 ml lyophilisate, we
observed a fall in protein binding towards control of 43.0
3.3% for theophylline and of 12.1 1.2% for phenytoin. The
sodium concentration in the different samples studied was 125
6,248 II and 500 23 mEq/liter for the lyophilisates of 0.5,
I and 2 ml, respectively. The inhibitory effect of ultrafiltrate
was thus more pronounced for theophylline than for phenytoin,
but this may in part be attributed to the progressively increasing
sodium content in the mixtures under study.
Influence of NaCI on protein binding
When NaCI was added to normal serum in varying concen-
trations, theophylline protein binding was inhibited progres-
sively in a dose dependent way (Table 2), but for a similar NaC1
concentration the protein binding inhibition was less pronounced
here than in the dose response studies with ultrafiltrate (Table
3). This suggests that the presence of sodium alone in these
ultrafiltrates was not sufficient to explain the entire effect of
theophylline protein binding inhibition observed in the lyophi-
lisates of different volumes of ultrafiltrate, and that there are
Table 3. Relative importance of NaCI in theophylline protein binding
inhibition in ultrafiltrate dose response studies
Expected Registered
NaCI inhibition inhibition
Lyophlized concentration of protein of protein
volume ml mEq/L binding binding
0.5 125 135
1 248 144b —26.3
2 500 —27.1 —43.0
a According to the measured NaCI concentration.
b Extrapolated from the data in Table 2.
still one or more other substances that are present in ultrafiltrate
that may inhibit theophylline protein binding.
Phenytoin protein binding was not influenced.
Influence of HPLC eluate on protein binding
Ultrafiltrate of normal and uremic serum was submitted to
HPLC elution, and the influence of each of the eluted fractions
on theophylline and phenytoin protein binding was evaluated.
Two characteristic chromatograms (one of normal and one of
uremic serum), and the respective degree of inhibition of the
different fractions on phenytoin and theophylline protein bind-
ing are illustrated in Figure 3.
For normal serum, there is an inhibition of theophylline
protein binding in fraction 5-8, whereas phenytoin protein
binding is not influenced. Ultrafiltrate of uremic serum inhibits
theophylline protein binding in fractions S to 7, 9 to 10 and 27 to
28, and phenytoin protein binding in fractions 27 to 28. Frac-
tions 27 to 28 correspond to the elution zone of hippuric acid.
The mean values of protein binding inhibition of the 30
fractions under study for normal serum samples and uremic
ultrafiltrates are summarized in Table 4. This table also illus-
trates the concentration of Na in the samples after lyophiliza-
tion and redilution in water. Overall, these results are similar to
those displayed in Figure 3. HPLC-fractions of ultrafiltrate of
normal serum do not influence the protein binding of phenytoin.
There is, however, a marked inhibition of theophylline protein
binding in fractions 5 to 7, with a maximum in fraction 5. The
evaluation of ultrafiltrate of uremic serum revealed that
phenytoin protein binding is inhibited in fractions 27 and 28.
Theophylline protein binding is inhibited in fractions 5 to 10
with a maximum in fraction 5 and another maximum in fractions
9 to 10. There is also an important inhibitory activity up to a
value of 18.6 16.3% in fractions 27 and 28. Fraction 5 contains
the highest concentration of Nat. Similarly, the concentration
0 1 2 0 1 2
A B Table 2. Effect of different NaCI concentrations on protein binding
0
—10
0
—10
—20
—30
—40
%
NaCI
concentration
mEqilirer
Relative changes in PB vs. normal (%)
Theophylline Phenytoin
50 —1.2 0.1 —1.3 0.1
100 —4.3 0.5 —1.3 0.1
200 —11.2 1.1 —1.0 0.1
300 —17.6 2.0 —0.6 0.1
400 —23.9 2.5 —1.4 0.1
500 —27.1 3.6 —1.6 0.3
600 —31.1 4.3 —1.4 0.1
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of the other electrolytes (K, C1) and the osmolality were high
in this fraction both in the chromatograms of normal and uremic
serum ultrafiltrate.
Identification of substances responsible for protein binding
inhibition
When chromatographing creatinine, pseudo-uridine, uric acid,
indoxyl sulphate and hippuric acid, it appeared that three of
these known urernic solutes were eluted on HPLC near the
zones with inhibitory activity on protein binding of theophylline
and/or phenytoin (Fig. 4A). Creatinine and pseudo-uridine were
eluted near to fraction 9-10, and hippuric acid eluted exactly in
fraction 27 and 28. The elution zone of these substances
corresponded to the elution zone of a major HPLC-peak when
uremic ultrafiltrate was chrornatographed (Fig. 4B). When
adding a standard solution of these substances to uremic
ultrafiltrate, the height of the existing peaks was increased,
without the creation of new peaks (Fig. 4C), suggesting that the
observed peaks corresponded exactly to the above uremic
solutes.
The respective effects of varying concentrations of urea,
creatinine, indoxyl sulphate and pseudo-uridine on protein
binding of theophylline and phenytoin is illustrated in Table 5.
Urea, creatinine and pseudo-uridine exerted no influence on the
protein binding of both theophylline and phenytoin. Indoxyl
sulphate influenced protein binding, hut only in a concentration
in excess of 50 mg/lOO ml. The influence of hippuric acid on
theophylline and phenytoin protein binding is illustrated in
Figure 5. Hippurate inhibited protein binding of phenytoin and
theophylline in a dose dependent manner. The inhibitory effect
was most pronounced for theophylline.
Discussion
In a first part of this study, the protein binding of several
drugs, that are currently used during chronic renal failure, is
evaluated. For some drugs, such as phenytoin [1—7] and diaze-
pam 8I, our findings are a confirmation of earlier reports,
showing a decrease in protein binding. For most other sub-
stances, no data on protein binding with progressive renal
dysfunction is available.
Five drugs (theophylline, phenytoin, methotrexate, diazepam
and prazosin) are characterized by a decrease of their protein
binding by up to 20% when renal function is progressively lost.
This means a relative increase of the free, active fraction of the
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Table 3. Characteristics of different HPLC elution ti-actions of ultrafihtrate of normal (N = 3) and uremic serum (N = 4)
Nornml serum Uremic serum
PB PB PB PB
Elution theophylline phenytoin Na theophylline phenytoin Na
fraction )iiY is. control5) ( is - control) ,uLq//iicr ( 7 is. control) ( i-s. control) ;nEq/Iiter
I 4.3 3.8 0.5 it 1.2 0 —1.1 5.5 --0.6 1.1 0
2 5.1 3.5 0.7 it 1.4 0 —3.9 8.8 —0.6 0.9 0
3 3.4± 2.3 0.5±0.3 0 —9.8± 17.6 —1.5±1.2 0
4 4.7 1.0 1.4 it 0.3 0 —9.5 16.6 - 0.4 1.0 0
5 --43.4 it (1.2 —3.2 4.7 408.0 33.9 —39.5 14.2 —4.6 0.9 441.3 5.9
6 —12.2 t- 1.9 - 2.0 it 0.1 11)6.5 10.6 --19.4 15.7 —2.1 2.3 120.3 21.3
7 —9.2 1.7 - 0.5 it 0.1 9.0 it 0.1 —10.7 14.3 —0.9 0.9 8.7 11.1
8 —3.9 1.4 —0.6 it ((.8 3.5 it 0.7 -6.8 14.3 —0.9 0.3 3.3 0.4
9 —0.5 -c ((.6 —0.6 it 0.8 2.0 0.! —12.6 7.9 —0.7 0.6 2.3 0.4
10 —0.6 0.8 —0.3 it 0.3 1.5 0.7 - 14.8 18.6 —0.4 0.3 0.7 0.4
II 4.8 2.6 0.3 it 0.6 1.0 0.1 —1.5 3.0 —0.8 1.0 0
12 3.5 0.7 0.9 0.2 1.0 it 0.! —1.3 2.4 —0.5 0.6 0
13 1.8 5.5 --0.9 0.8 0 -1.2 2.2 —1.6 it 1.4 0
14 1.1 4.3 --1.4 it 0.1 0 —0.9 0.9 —1.7 1.2 0
IS 4.2 .6±0.6 0 —1.7± .7 —1.3±1.0 1)
16 3.7±3.9 -1.1±0.9 0 —0.4±3.( —1.4±1.0 0
17 3.7 5.8 —0.2 0 0
1.5 1.1 0 0
it 0 —1.9
3.0 0 0it 0 0
22 2.9± 5.2 1.9 t 0.3 (1 —1.4 2.6 —0.8±0.2 0
23 3.3 2.7 1.3 it 0.2 (1 —2.1 2.7 —1.3 1.0 0
24 3.7 4.0 1.8 it ((.2 0 —1.6 2.8 —0.4 0.6 0
25 0.5 5.0 —1.1 it 2.2 0 —2.! 2.5 —0.8 0.6 0
26 0.9 5.7 0.5 it 0.9 0 —2.0 1.5 —0.9 0.5 0
27 5.8 0.8 1.1 it 0.1 0 —15.9 7.8 —10.0 7.6 0
28 2.8 4.2 1.0 it 0.9 0 —18.6 16.3 —3.9 3.8 0
29 2.4 it 2.9 0.6 it 1.1 0 —2.9± 2.5 —1.9± 2.7 0
30 0.0± 2.6 1.1 it 1.8 0 —3.8 2.9 —1.0± 0.5 0
PB, protein binding
Control. ultrafiltrate of seru iii of healthy persons
drug since for most drugs total (bound plus unbound) but not
free concentrations are monitored, these data suggest that for
these drugs, in renal failure, lower total drug serum concentra-
tions should be pursued than under normal conditions, and (hal
at "normal'' total drug concentrations toxic side effects may be
expected.
The fall in drug binding capacity for diazepam and prazosin
by only 2% for dialyzed patients compared to healthy
controls, appears at the outset less important than the decrease
for theophylline, phenytoin and methotrexate. II should how-
ever he stressed that the protein binding in healthy controls of
both diazcpam and prazosin is extremely high, so that appar-
ently minor changes in the bound fractions may induce impor-
tant disturbances in the free, unbound and active fractions. For
diazepam fir example, the tree traction increases from 1.7% in
healthy controls to 3.4% in dialyzed patients. This corresponds
to a twofold rise of the available active drug and may have
important therapeutic consequences.
For drugs in which a decrease in protein binding with
progressive renal failure was noted. there was a highly signifi-
cant negative correlation between protein binding and creati-
nine level (Fig. I), suggesting that the mechanisms involved
may progressively become more important with the loss of
renal function.
Several pathophysiological systems have been proposed to
explain this decrease in protein binding dui-ing the course of
renal failure. such as a decrease in proteinemia or albuminemia
[I]. changes in protein structure [1, 131 and/or competitive
inhibition of binding by uremic accumulation products 14—7, 10,
11, 14, 15].
Several protein structures are known to bind drugs and other
substances, such as albumin. lipoproteins, gammaglobulin and
alpha1-acid glycoprotein. The plasma protein that probably is
most prominent with this role is albumin. Our study demon-
strated no significant change of plasma albumin concentration
with progression of renal failure and there was no significant
correlation between protein binding on one hand, and protein
and albumin concentration on the other. Similarly, Kinniburgh
and Boyd found no major changes in the structure of serum
proteins, with progressive uremia [161. It is likely therefore that
protein concentration and/or structure play a minor role in drug
protein binding in renal failure, and that other solutes which
accumulate in renal failure may rather interfere in the compet-
itive binding of drugs to protein.
This hypothesis was confirmed by the finding of a dose
dependent decrease of theophylline and phenytoin protein
binding by ultrafiltrate of uremic serum.
in a second part of the study, we therefore tried to discern
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Fig. 4. High performance liquid chromatogram f a standard solution
(A) containing creatinine (1), pseudo-aridine (2), uric' acid (3), indoxyl
sulphate (4) and hippuric acid (5), of' aremic ultrafiltrate (B), and qf
uremic ultrafiltrate after the addition of the standard solution (C). Each
of these substances gives rise to a distinct peak. Their elution zone
corresponds to the elution zone of existing peaks on HPLC of uremic
ultrafiltrate. After addition of the standard solution to uremic ultrafil-
trate, the height of existing peaks is increased without the creation of
new peaks, Creatinine and pseudo-uridine are eluted in the proximity of
elution zones 9 and 10, and hippuric acid is eluted exactly in fractions
27 and 28.
which factors were responsible for this inhibition, by evaluating
the influence of 30 different HPLC fractions of ultraflltrate on
protein binding. This approach allowed the direct evaluation of
protein binding inhibitors in uremic biological fluids, The most
important finding of this part of the study was a substantial
decrease of both phenytoin and theophylline protein binding in
Table 5. tnfluence of different concentrations of urea, creatinine,
indoxyl sulphate and pseudo-uridinc on protein binding
Substance Concentration
Relative changes in PB vs.
normal %
Theophylline Phenytoin
UreaN 5 200 mg/l00 ml300 mg/lOO ml
400 mg/l00 ml
500 mg/l00 ml
—2.2 t 4.3
—3.0 3.6
—2.1 3.1
—2.8 t 3.3
—1.0 0.3
—0.4 0.2
—0.4 0.2
—0.6 0.2
Creatinine
N = 5
5 mg/l00 ml
10 mg/lOO ml
15 mg/100 ml
20 mg/tOO ml
—3.8 4.7
—3.7 4.1
—4.1 4.4
—3.9 3.4
0.1 0.5
0.6±0.1
0.1 0.1
0.2 0.1
Indoxyl sulphateN=5
10 mg/l00 ml
2Omg/lOOmI
50 mg/l00 ml
100 mg/tOO ml
200 mg/l00 ml
—0.6 1.3
—1.9±0.6
—4.7 1.5
—11.8 1.5
—24.9 1.6
—0.3 0.3
—(.3±0.2
—5.1 0.4
—14.7 0.4
—21.2 0.5
Pseudo-uridineN 5 0.25 mg/l00 ml0.50 mg/l00 ml
1.OOmg/lOOmI
2.00 mg/lOO ml
5.00 mg/l00 ml
—1.6 1.2
—5.7 1.1
—4.8±2.1
—6.3 1.6
—3.6 1.7
—1.4 0.2
—1.1 0.1
—1.2±0.1
—1.4 0.1
—(.4 0.7
the HPLC fractions 27 to 28, the elution zone of hippuric acid,
suggesting that the major dialyzable and/or ultrafiltrable factor
inhibiting the protein binding of these two drugs is hippurate.
Earlier indirect results obtained after the study of urine of
healthy persons [10, 17] and of solutions partially mimicking the
composition of uremic serum [lii, had suggested the inhibitory
influence of hippurate on phenytoin protein binding. Our data
confirm these earlier results, by a direct evaluation and indicate
that the negative influence of hippurate is not limited to pheny-
tom alone, but that at least one other drug is similarly affected.
Although the metabolic origins of hippuric acid are multiple,
and precursors of the substance may be found in coffee, tea,
fruits and may be produced by intestinal flora and endogenously
[l8J, one source specific to dialysis patients is benzyl alcohol
used as a preservative in some heparin brands which is entirely
metabolized to hippurate [191.
In consequence, brands of heparin containing benzyl alcohol
should be used with care in patients on theophylline and
phenytoin. Monitoring of plasma hippurate levels might also be
advisory in such patients.
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Fig. 5. Effect of different concentrations of hippuric acid, added to
normal serum after lyophilization, on protein binding of theophylline
(left) and phenytoin (right).
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It should be stressed that our dialysis patients do not use
heparin thai contains benzyl alcohol, so that it may be assumed
that the protein binding inhibition observed in the present study
is even less pronounced than is likely in patients using brands of
heparin containing benzyl alcohol.
To allow a correct estimation of the magnitude of the hippur-
ate related protein binding inhibition effect, it is important to
stress that the hippuric acid concentrations of the ultrafiltrates
in the present study averaged 7.53 2.94 mg/l00 ml (means
SD, unpublished results). In a recent study from our lab, serum
hippuric acid concentration was found to be between 2.5 to 37.2
mgIlOO ml in hemodialyzed uremics (mean value: 9.7 8.5
mgIlOO ml) [20].
Extrapolation of these data to Figure 5, reveals that similar
concentrations of hippuric acid would result in a protein binding
inhibition in dialyzed patients by maximum 10 and 5% for
theophylline and phenytoin, respectively, suggesting that other
ligands may play an additional role as well.
Apart from the elution zone of hippuric acid, two other zones
of binding inhibition were observed in the theophylline studies.
One zone of binding inhibition corresponded to a number of
fractions containing mainly NaCI. In both normal and uremic
ultrafiltrate (Table 4) a marked parallelism between protein
binding inhibition of theophylline and the electrolyte content in
the fifth and nearby fractions was present; this suggests that the
protein binding inhibition of theophylline in these fractions may
be related to the electrolyte content. Sodium chloride in dif-
ferent concentrations also caused a dose dependent inhibition
of theophylline protein binding (Table 2).
These data emphasize the importance of taking into account
sodium concentrations in protein binding studies and point to
the effectiveness of HPLC for the fractionation of serum
samples since with this technique, electrolytes are clearly
separated from the elution fractions containing the major or-
ganic substances.
A last zone of inhibitory activity was seen in fractions 9 and
10 of HPLC eluate; we were able to recognize only two
UV-absorbing uremic solutes in or near to these elution frac-
tions: creatinine and pseudo-uridine. Neither of these com-
pounds inhibited protein binding, when dissolved in concentra-
tions comparable to those observed in renal failure and in
normal serum (Table 5). It is conceivable that another as yet
unidentified compound plays an inhibitory role in this fraction.
In view of the fact that no new substances responsible for
drug protein binding inhibition were found, except perhaps for
an unidentified fraction eluting in HPLC fractions 9-10, our data
suggest that at least some of the binding inhibitors are highly
protein-bound as such, so that they do not appear in measurable
amounts in the ultrafiltrate. Alternatively, loss of the inhibitor,
due to binding to the filtration membrane or failure to elute from
the HPLC-column, should be considered.
Indoxyl sulphate has been suggested as being responsible for
a part of the protein binding inhibition of diazepam, warfarin
and phenytoin [II, 21—23]. The role of indoxyl sulfate in the
protein binding defect of phenytoin could not be confirmed in
the present study. We found no inhibitory activity in the HPLC
elution zone of indoxyl sulphate (fractions 24-25, Fig. 3), and
although this substance was shown to decrease theophylline
and phenytoin protein binding, at concentrations from 50 to 100
mg/100 ml (Table 5), these concentrations are, however, much
higher than those found in renal failure patients [II], or even
uremic coma [241.
Of the drugs studied, four drugs (propranolol, cimetidine,
clonidine and to a certain extent also imipramine) showed
increased protein binding with progressive renal failure. An
increase in drug protein binding decreases the available free
concentration and modifies the therapeutic effect of the drugs in
a way that their activity is diminished. Thus, for these drugs
higher total concentrations should be pursued in renal failure, if
no free concentrations can be measured. The possibility exists
that, by some mechanism, the number of binding sites for
certain drugs increases with the progressive loss of renal
function. The fact that all drugs in this study which show a rise
in protein binding with renal failure are basic might be a
possible explanation, since basic drugs might bind preferen-
tially to alpha1-acid glycoprotein (AAG) [25, 26], and it is
recognized that AAG concentrations rise during renal failure
[8]. A similar binding increase associated with a rise in serum
AAG concentration has also been observed for imipramine after
severe burn injury [27], in cardiac patients [28], and for pro-
pranolol in rats with severe inflammation [29].
It is notable that results of drug protein binding were similar
in the patients treated with hemodialysis and hemodiafiltration,
so that the data were pooled. This observation might lead one to
suppose that middle molecules or poorly dialyzed but easily
filtered solutes are not responsible for the binding inhibition of
renal failure. However, the results considered are pre-dialysis
values, so that it is difficult to make any definite conclusion on
the direct influence of factors related to the dialysis technique
as such on drug protein binding.
The present data of altering relations between bound and
unbound fractions of drugs during the progression of renal
failure emphasize the importance of monitoring free rather than
total drug fractions in uremic patients. When monitoring total
drug concentrations, and if protein binding is decreased, a high
normal total drug level corresponds to an increased level of free
and active drug, and vice versa.
Finally, it could be argued that for four substances (theophyl-
line, methotrexate, clonidine and cimetidine) data concerning
renal failure are not available in the literature because these
drugs are poorly bound in normal subjects, so that they were
not submitted to further evaluation. It should be stressed
however, that in renal failure for a drug such as theophylline, a
decrease in protein binding from 63.6 to 43.5% (Table 1), will
result in a change in maximum allowable total drug serum
concentration from 20 to 13 j.rg/ml, which may have impor-
tant clinical implications, in the search for optimal non-toxic
treatment schedules.
In conclusion, our study indicates that:
I. The protein binding of propranolol, clonidine, cimetidine
and to a lesser extent imipramine is increased with progres-
sive renal failure, while the protein binding of diazepam.
methotrexate, phenytoin and theophylline is decreased.
2. There is a highly significant negative correlation between the
binding inhibition of the latter four drugs and creatinine
concentration, suggesting a relationship between the pro-
gressive accumulation of uremic solutes and the protein
binding defect in renal failure. This binding defect is most
important for theophylline and phenytoin.
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3. Lyophilization of different volumes of ultrafiltrate inhibits
the binding of theophylline and phenytoin in a dose depen-
dent way.
4. Sodium chloride inhibits the protein binding of theophylline.
and the salt content of fractions should always be taken into
account when undertaking protein binding studies.
5. HPLC is a simple and useful method to separate NaCI from
the other organic compounds, especially uremic retention
products.
6. Hippuric acid appears to be the major dialyzable and/or
ultrafiltrable substance affecting protein binding of theophyl-
line and phenytoin.
Reprint requests to R. Vanho/der, Nephrologv Department, Unim'er—
si/V Hospital, Dc Pin/c/ann /85, B—9000 Ghent, Belgium.
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